Valneva Announces Successful Outcome of its AGM and Appointment of two New Supervisory Board Members
24 Juin 2022 - 7:05AM
Valneva Announces Successful Outcome of its AGM and Appointment of
two New Supervisory Board Members
Saint-Herblain
(France), June
24,
2022 – Valneva SE (Nasdaq: VALN;
Euronext Paris: VLA), a specialty vaccine company, today announced
that all the resolutions recommended by the Management Board were
approved by the shareholders at its Annual General Meeting (AGM)
held yesterday in Paris.
Among the adopted resolutions were approval of
the 2021 financial statements, delegations for the management board
to increase Valneva’s share capital and/or issue financial
instruments, and the appointment, for a three-year term, of two new
Supervisory Board members.
Bpifrance Participations was appointed to
Valneva’s Supervisor Board and will be represented by Maïlys
Ferrère. Ms. Ferrère, a French national, is Director of Large
Venture Investments at Bpifrance, France’s state-owned investment
bank. In her role at Bpifrance, she sits on various boards of
Euronext-listed companies. Before joining Bpifrance Large Venture
in 2013, Ms. Ferrère was an Investment Director at the Fonds
Stratégique d’Investissement. Prior to this, Ms. Ferrère had a
career in the banking industry, focusing on equity capital markets
in various financial institutions. She graduated from Institut
d’Etudes Politiques de Paris.
James Edward Connolly, an American national, was
also appointed to Valneva’s Supervisory Board. Mr. Connolly is a
seasoned business executive with more than three decades of
experience in the life sciences industry. Since 2013, Mr. Connolly
has been serving on a number of boards for a variety of vaccine,
biopharmaceutical and investment organizations. From 2010 to 2013,
Mr. Connolly was President and CEO of Aeras (now IAVI.) Prior to
this, he had a long and successful 24-year career at Wyeth (now
Pfizer), where he held a series of senior roles, the last two of
which were Executive Vice President and General Manager, Wyeth
Vaccines and President, Wyeth Canada. During his tenure leading
Wyeth Vaccines, Mr. Connolly played a leading role building the
company’s vaccines business into one of the top four global
manufacturers and creating the first true blockbuster vaccine,
Prevnar, with sales in excess of $3 billion.
Additionally, the term of office of Supervisory
Board members Frédéric Grimaud, James Sulat, and Anne-Marie Graffin
was renewed until June 2025. In a separate meeting, Frédéric
Grimaud was re-elected as Chairman of Valneva’s Supervisory
Board.
Valneva also confirmed during the AGM that
initiation of the Phase 3 study of Lyme disease vaccine candidate
VLA15 is planned in the third quarter of 2022 and that it is
expecting to submit the Biologics License Application (BLA) for its
chikungunya vaccine candidate VLA1553 to the Food and Drug
Administration (FDA) in the second half of 2022.
The AGM’s voting results will be made available
in the “Investors & Media” section of Valneva’s corporate
website in the coming days.
About Valneva SEValneva is a
specialty vaccine company focused on the development and
commercialization of prophylactic vaccines for infectious diseases
with significant unmet medical need. The Company takes a highly
specialized and targeted approach to vaccine development and then
applies its deep understanding of vaccine science to develop
prophylactic vaccines addressing these diseases. Valneva has
leveraged its expertise and capabilities both to successfully
commercialize two vaccines and to rapidly advance a broad range of
vaccine candidates into and through the clinic, including
candidates against Lyme disease, the chikungunya virus and
COVID-19.
Media
& Investor ContactsLaëtitia Bachelot-FontaineVP Global
Communications & European Investor RelationsM +33 (0)6 4516
7099
laetitia.bachelot-fontaine@valneva.com |
Joshua
Drumm, Ph.D.VP Global Investor RelationsM +001 917 815
4520joshua.drumm@valneva.com |
Valneva Forward-Looking
StatementsThis press release contains certain
forward-looking statements relating to the business of Valneva,
including with respect to the progress, timing, results and
completion of research, development and clinical trials for product
candidates and estimates for future performance. In addition, even
if the actual results or development of Valneva are consistent with
the forward-looking statements contained in this press release,
those results or developments of Valneva may not be sustained in
the future. In some cases, you can identify forward-looking
statements by words such as "could," "should," "may," "expects,"
"anticipates," "believes," "intends," "estimates," "aims,"
"targets," or similar words. These forward-looking statements are
based largely on the current expectations of Valneva as of the date
of this press release and are subject to a number of known and
unknown risks and uncertainties and other factors that may cause
actual results, performance or achievements to be materially
different from any future results, performance or achievement
expressed or implied by these forward-looking statements. In
particular, the expectations of Valneva could be affected by, among
other things, uncertainties involved in the development and
manufacture of vaccines, unexpected clinical trial results,
unexpected regulatory actions or delays, competition in general,
currency fluctuations, the impact of the global and European credit
crisis, and the ability to obtain or maintain patent or other
proprietary intellectual property protection. Success in
preclinical studies or earlier clinical trials may not be
indicative of results in future clinical trials. In light of these
risks and uncertainties, there can be no assurance that the
forward-looking statements made during this presentation will in
fact be realized. Valneva is providing the information in these
materials as of this press release and disclaim any intention or
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise.
- 2022_06_24_VLA_Post_AGM_PR_EN_Final
Valneva (EU:VLA)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Valneva (EU:VLA)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024